7Baggers
Quarterly
Annual
    Unit: USD2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 
      
    		                         
      operating activities:
    		                         
      net income
    		-184,937,000 -183,758,000 -169,608,000 -267,389,000 -164,254,000 -75,544,000 -36,160,000 -170,328,000 -179,488,000 -160,703,000 -142,732,000 -140,570,000 -140,193,000 -2,559,000 -201,330,000 -152,282,000 -161,016,000 -102,074,000 -171,082,000 -135,025,000 -130,167,000 -136,214,000 -104,082,000 -84,151,000 -60,733,000 
      adjustments to reconcile net income to net cash from operating activities:
    		                         
      stock-based compensation
    		35,262,000 37,241,000 25,882,000 30,127,000 27,162,000 21,454,000 17,057,000 37,025,000 22,600,000 27,178,000 21,907,000 21,789,000 17,361,000 28,287,000 24,122,000 19,774,000 16,042,000 30,112,000 33,577,000 12,146,000 17,699,000 18,392,000 10,222,000   
      loss on extinguishments of debt
    		                         
      noncash interest expense on deferred royalty obligations
    		                         
      amortization of debt discount and issuance costs
    		                         
      depreciation and amortization
    		1,398,000 1,317,000 1,284,000 1,367,000 1,538,000 1,574,000 1,596,000 1,585,000 1,639,000 1,637,000 1,633,000 1,660,000 1,645,000 1,582,000 1,884,000 1,526,000 265,000        374,000 
      noncash lease expense
    		1,213,000 1,236,000 994,000 991,000 1,026,000 1,024,000 1,069,000 1,008,000 1,000,000 992,000 1,032,000    1,545,000 1,533,000          
      net income from equity method investments
    		15,834,000 20,189,000 15,556,000 16,695,000                      
      change in fair value of the embedded derivative associated with the deferred royalty obligation
    		                         
      noncash income from an equity method investment
    		                         
      gain on deconsolidation of subsidiaries
    		   0 -52,027,000                     
      gain from investment in equity securities
    		   0 0 0 -8,136,000    -964,000               
      other noncash adjustments
    		4,247,000 -1,491,000 -3,973,000 -697,000 -148,000 -3,542,000 1,631,000 565,000 -56,000 -125,000 -203,000 -4,083,000 945,000 3,138,000 604,000 -1,421,000 1,307,000 2,110,000 5,096,000 -4,643,000 4,844,000 1,446,000 1,034,000   
      changes in operating assets and liabilities:
    		                         
      accounts receivable
    		-39,650,000 38,397,000 -110,543,000                       
      inventories
    		-6,774,000 -13,389,000 -3,193,000                       
      prepaid expenses and other current assets
    		5,218,000 -22,258,000 -487,000 3,625,000 -11,037,000 -3,161,000 -3,345,000 -1,722,000 -2,037,000 4,599,000 -3,542,000 3,599,000 7,093,000 -364,000 -2,657,000 -519,000 -5,143,000 -48,000 1,448,000 -1,668,000 -7,025,000 -1,212,000 2,846,000 -951,000 -9,196,000 
      other assets
    		742,000 -1,761,000 1,587,000 1,970,000 -1,370,000 498,000 444,000 -2,989,000 1,411,000 515,000 -483,000 876,000 1,404,000 790,000 7,901,000 -886,000 -3,207,000 390,000 -6,113,000 -1,952,000 771,000 -231,000 -734,000 -15,265,000 413,000 
      accounts payable
    		-7,432,000 -1,055,000 17,571,000 -3,745,000 -3,601,000 14,785,000 -5,927,000 6,184,000 694,000 -298,000 -3,800,000 1,376,000 1,365,000 -1,276,000 -1,814,000 1,473,000 -11,665,000 11,233,000 1,792,000 -1,282,000 -3,436,000 -251,000 4,234,000 -1,418,000 -3,385,000 
      accrued compensation and benefits
    		18,849,000 3,726,000 -19,363,000 11,406,000 13,958,000 6,591,000 -14,969,000 11,958,000 6,915,000 7,298,000 -18,369,000 6,760,000 280,000 7,474,000 -16,876,000 11,821,000 4,051,000 4,487,000 -12,981,000 6,194,000 4,446,000 5,619,000 -7,670,000 5,737,000 2,844,000 
      accrued research and development liabilities
    		3,324,000 -2,335,000 -642,000 -6,725,000 8,387,000 -4,101,000 11,168,000 689,000 778,000 -8,766,000 -2,556,000 -4,761,000 -5,501,000 6,771,000 -818,000 6,492,000 2,223,000 -3,671,000 6,134,000 2,166,000 -12,341,000 7,719,000 8,626,000 7,697,000 3,779,000 
      operating lease liabilities
    		-1,640,000 -1,647,000 -1,470,000 -1,443,000 -1,478,000 -1,386,000 -1,595,000 -1,158,000 -1,228,000 -1,193,000 -1,250,000 -1,426,000 -1,471,000 -1,528,000 -1,820,000 -1,648,000 -1,698,000 -1,438,000 -1,338,000 -1,163,000 -891,000 -862,000 -556,000   
      deferred revenue
    		-2,989,000 -3,920,000 -2,571,000 1,300,000 -1,661,000 -1,788,000 24,024,000 -974,000 -1,280,000 -1,436,000 -1,748,000 -1,707,000 328,000             
      other liabilities
    		                       0 83,000 
      net cash from operating activities
    		-109,574,000 -80,681,000 -199,235,000 -195,326,000 -180,566,000 74,703,000 -219,537,000 -124,819,000 -145,226,000 -113,353,000 -144,322,000 -93,243,000 -135,163,000 -30,453,000 -160,635,000 -133,895,000 -121,561,000 -91,713,000 -150,765,000 -96,261,000 -131,684,000 -87,849,000 -83,920,000 -76,203,000 -49,996,000 
      capex
    		-470,000 0 0 -47,000 -137,000 -54,000 -695,000 -435,000 -431,000 -428,000 -12,000 -801,000 -759,000 -2,402,000 -859,000 -2,536,000 -6,462,000 -2,287,000 -1,961,000 -2,146,000 -549,000 -346,000 -4,477,000 -1,747,000 -381,000 
      free cash flows
    		-110,044,000 -80,681,000 -199,235,000 -195,373,000 -180,703,000 74,649,000 -220,232,000 -125,254,000 -145,657,000 -113,781,000 -144,334,000 -94,044,000 -135,922,000 -32,855,000 -161,494,000 -136,431,000 -128,023,000 -94,000,000 -152,726,000 -98,407,000 -132,233,000 -88,195,000 -88,397,000 -77,950,000 -50,377,000 
      investing activities:
    		                         
      purchases of marketable securities
    		-2,968,000   0 0 -49,416,000 -44,395,000 0 -9,972,000   -2,858,000 -15,024,000 -63,889,000 -55,722,000 -14,414,000 -65,544,000 -130,643,000 -379,291,000 -18,050,000 -101,001,000   -15,154,000  
      maturities of marketable securities
    		   0 40,000,000   0 41,000,000 23,550,000 18,000,000 26,869,000 158,900,000 107,224,000 186,695,000 75,000,000 66,266,000 139,734,000 99,200,000 110,121,000 56,500,000 40,016,000 42,500,000   
      purchases of investments in equity securities
    		   0 0 0 -20,271,000                   
      proceeds from sales of investments in equity securities
    		   0 0 0 63,229,000                   
      proceeds from special cash dividends received from an investment in equity securities
    		                         
      payment for intangible assets
    		-2,400,000                         
      purchases of property and equipment
    		-470,000   -47,000 -137,000 -54,000 -695,000 -435,000 -431,000 -428,000 -12,000 -801,000 -759,000 -2,402,000 -859,000 -2,536,000 -6,462,000 -2,287,000 -1,961,000 -2,146,000 -549,000 -346,000 -4,477,000 -1,747,000 -381,000 
      decrease in cash and cash equivalents resulting from deconsolidation of subsidiaries
    		   0 -42,000                     
      net cash from investing activities
    		4,464,000 -13,002,000 -1,595,000 -3,237,000 38,226,000 3,039,000 22,753,000 -66,000 37,682,000 4,119,000 12,298,000 17,965,000 146,857,000 149,702,000 138,623,000 21,800,000 58,968,000 458,000 -282,052,000 83,018,000 -45,050,000 -128,984,000 38,023,000 -16,901,000 -197,342,000 
      financing activities:
    		                         
      proceeds from issuance of 2031 notes
    		0 0 575,000,000                       
      issuance costs and discounts associated with 2031 notes
    		0 0 -12,034,000                       
      repurchase of common stock
    		0 0 -48,276,000               -5,308,000 -50,000,000 0 0 0 -75,000,000   
      proceeds from a royalty obligation under the royalty purchase agreement
    		                         
      issuance costs associated with a royalty obligation under the royalty purchase agreement
    		                         
      proceeds from term loan under the amended financing agreement
    		                         
      issuance costs and discounts associated with term loan under the amended financing agreement
    		                         
      repayment of term loans
    		0 0 -459,000,000                       
      repayments of deferred royalty obligations
    		                         
      proceeds from issuance of common stock through public offerings
    		   0 -18,000 -495,000 315,254,000                   
      proceeds from common stock issuances under espp
    		3,177,000                         
      proceeds from stock option exercises, net of repurchases
    		4,843,000 7,159,000 2,521,000 2,848,000 30,000 241,000 537,000 786,000 4,910,000 119,000 193,000 57,000 449,000 56,000 104,000 2,349,000 3,078,000 3,752,000 7,464,000 10,002,000 820,000 1,367,000 734,000   
      transactions with noncontrolling interests
    		0 750,000 800,000     -2,301,000         3,430,000         
      repurchase of rsu shares to satisfy tax withholding
    		-3,025,000 -1,995,000 -1,776,000 -1,404,000 -1,443,000 -1,743,000 -2,936,000                   
      net cash from financing activities
    		-894,000 302,041,000 60,328,000 473,931,000 707,000 -5,729,000 279,548,000 -4,523,000 307,040,000 -1,231,000 150,249,000 6,377,000 1,445,000 -20,796,000 -160,000 325,381,000 -135,456,000 -1,391,000 547,912,000 4,531,000 2,782,000 703,000 439,173,000 42,904,000 367,508,000 
      net increase in cash, cash equivalents and restricted cash
    		-106,004,000 208,358,000 -140,502,000 275,368,000 -141,633,000 72,013,000 82,764,000 -129,408,000 199,496,000 -110,465,000 18,225,000 -68,901,000 13,139,000 98,453,000 -22,172,000 213,286,000 -198,049,000 -92,646,000 115,095,000 -8,712,000 -173,952,000 -216,130,000 393,276,000 -50,200,000 120,170,000 
      cash, cash equivalents and restricted cash at beginning of period
    		0 0 683,244,000  0 0 394,732,000 0 0 0 416,884,000  0 0 396,365,000 0 0 0 358,679,000 0 0 0 364,197,000 0 0 
      cash, cash equivalents and restricted cash at end of period
    		-106,004,000 208,358,000 542,742,000  -141,633,000 72,013,000 477,496,000 -129,408,000 199,496,000 -110,465,000 435,109,000  13,139,000 98,453,000 374,193,000 213,286,000 -198,049,000 -92,646,000 473,774,000 -8,712,000 -173,952,000 -216,130,000 757,473,000 -50,200,000 120,170,000 
      supplemental disclosure of cash flow information:
    		                         
      cash paid for interest
    		               1,535,000 17,425,000 1,901,000 8,913,000 2,041,000 9,159,000 2,068,000 2,054,000 1,756,000 1,753,000 
      cash paid for income taxes
    		                         
      supplemental disclosures of noncash investing and financing information:
    		                         
      unpaid property and equipment
    		                  1,787,000       
      transfers to noncontrolling interests
    		                         
      reconciliation of cash, cash equivalents and restricted cash:
    		                         
      cash and cash equivalents
    		                         
      restricted cash — included in “prepaid expenses and other current assets”
    		                         
      restricted cash — included in “other assets”
    		                         
      total cash, cash equivalents and restricted cash at end of periods shown in the condensed consolidated statements of cash flows
    		                         
      losses on extinguishments of debt
    		                         
      accretion of debt
    		 27,465,000 25,641,000 10,364,000 1,716,000 1,668,000 2,015,000 2,183,000 2,144,000 2,242,000 2,338,000 2,101,000 2,086,000 1,900,000 2,483,000 1,752,000 1,390,000 1,404,000 1,249,000       
      gain on deconsolidation of a subsidiary
    		                         
      dividend from investment in equity securities
    		                         
      other current liabilities
    		 23,664,000 2,945,000                       
      proceeds from royalty obligation under royalty purchase agreement
    		                         
      issuance costs associated with royalty obligation under royalty purchase agreement
    		                         
      proceeds from term loan under amended financing agreement
    		                         
      issuance costs and discounts associated with term loan under amended financing agreement
    		                         
      repayment of deferred royalty obligation
    		 -1,861,000 -144,000                       
      loss on extinguishment of debt
    		  21,155,000 0 0 0 26,590,000                   
      proceeds from special cash dividends received from investments in equity securities
    		   0 0 0 25,682,000                   
      payment for an intangible asset
    		  -1,595,000 -3,190,000 -1,595,000 -2,393,000 -797,000      0             
      proceeds from bridgebio common stock issuances under espp
    		  3,237,000 0 2,138,000 0 2,364,000 1,000 1,588,000 0 1,809,000  1,592,000 0 966,000 0 2,169,000 0 1,652,000       
      accrual of payment-in-kind interest on term loan
    		       3,465,000 0 3,403,000 3,339,000               
      fair value of shares issued under a license agreement
    		            0             
      loss on sale of certain assets
    		           0 0 0 6,261,000           
      impairment of long-lived assets
    		           0 67,000 0 12,653,000           
      gain from sale of priority review voucher, excluding transaction costs
    		           0 0             
      gain from recognition of receivable from licensing and collaboration agreement
    		           0 0 0 -12,500,000           
      accrued professional and other liabilities
    		   10,801,000 -5,522,000 166,000 -1,256,000 6,572,000 -7,385,000                 
      proceeds from sale of priority review voucher
    		            0             
      proceeds from sale of certain assets
    		           0 0 0 10,000,000           
      proceeds from royalty obligation under funding agreement
    		                         
      issuance costs and discounts associated with royalty obligation under funding agreement
    		                         
      other financing activities
    		         -1,180,000 5,743,000               
      cash, cash equivalents and restricted cash at beginning of year
    		                         
      cash, cash equivalents and restricted cash at end of year
    		                         
      receivables from licensing and collaboration agreements
    		    182,000 234,834,000 -233,743,000                   
      proceeds from term loan under financing agreement
    		    0 0 450,000,000                   
      issuance costs and discounts associated with term loan under financing agreement
    		    0 -3,732,000 -12,254,000                   
      repayment of term loan under loan and security agreement
    		    0 0 -473,417,000                   
      net income from equity method investment
    		                         
      fair value adjustment of warrants
    		       -1,036,000 274,000 -111,000 -111,000 125,000 56,000 538,000 852,000           
      loss on deconsolidation of pellepharm
    		       0 0 0 1,241,000               
      decrease in cash and cash equivalents resulting from deconsolidation of pellepharm
    		       0 0 0 -503,000               
      (gain) income from investment in equity securities
    		                         
      leo call option income
    		                  -5,550,000       
      loss on early extinguishment of debt
    		                         
      receivable from licensing and collaboration agreements
    		       3,419,000 3,443,000 2,148,000 6,318,000 16,001,000 -3,825,000 -7,273,000 10,266,000 -12,039,000 27,653,000         
      sales of marketable securities
    		               -36,234,000          
      purchases of investment in equity securities
    		       -29,224,000 -6,810,000 -24,030,000 -47,474,000 -29,250,000 -15,382,000 -2,768,000 -8,162,000 -29,423,000          
      sales of investment in equity securities
    		       29,593,000 13,895,000 24,781,000 42,287,000 24,005,000 19,122,000 3,037,000 6,671,000 29,407,000          
      increase in cash and cash equivalents from consolidation of pellepharm
    		               0 0         
      proceeds from issuance of common stock through private placement offering
    		       -454,000                  
      proceeds from issuance of common stock through follow-on offering
    		       0 0 1,033,000 143,016,000               
      proceeds from issuance of common stock through atm offering
    		       0                  
      proceeds from issuance of 2029 notes
    		                         
      issuance costs and discounts associated with issuance of 2029 notes
    		                         
      purchase of capped calls
    		               0 0 0 -61,295,000 0 0 0 -49,280,000   
      repurchases of common stock
    		                         
      repurchase of eidos noncontrolling interest, including direct transaction costs
    		               0 -250,000 -4,516,000 -80,324,000       
      proceeds from term loan, net of issuance costs
    		                         
      repayment of term loan
    		           0 0    0         
      income from investment in equity securities
    		                         
      repurchase of shares to satisfy tax withholding
    		        -2,610,000 -1,203,000 -512,000  -596,000 -366,000 -110,000 -711,000 -733,000 -2,281,000 -1,021,000 -471,000      
      issuance costs associated with term loan
    		            0 0 -1,120,000           
      accrued professional services
    		          2,225,000 -2,440,000 -1,954,000 772,000 -1,374,000 1,811,000 -1,153,000 1,859,000 -360,000 1,256,000 -5,237,000 5,465,000 923,000   
      other accrued and other long-term liabilities
    		          -8,597,000 -6,530,000 -4,590,000 11,270,000 -2,883,000 13,636,000          
      operating activities
    		                         
      net gain from investment in equity securities
    		                         
      fair value of shares issued under license agreements
    		                         
      leo call option expense
    		               0 0   352,000 -78,000 1,737,000 -539,000 57,000 -276,000 
      acquired in-process research and development assets
    		                       0 1,060,000 
      receivable from a related party
    		                8,500,000 -8,500,000 -462,000 8,000,000      
      investing activities
    		                         
      proceeds from sale of priority review voucher, excluding transaction costs
    		                         
      other investing activities
    		                         
      financing activities
    		                         
      proceeds from issuance of 2029 notes in 2021 and 2027 notes in 2020
    		               0 0 0 747,500,000       
      issuance costs and discounts associated with issuance of 2029 notes and 2027 notes
    		               0 0 0 -16,064,000       
      proceeds from issuance of noncontrolling interests
    		                         
      repurchase of common stock to satisfy tax withholding
    		                         
      proceeds from at-the-market issuance of noncontrolling interest by eidos
    		                   0 0 0 24,094,000   
      proceeds from issuance of common stock through at-the-market offering
    		                         
      repurchase of noncontrolling interest
    		                       0 -26,383,000 
      supplemental disclosures of cash flow information:
    		                         
      supplemental disclosures of non-cash investing and financing information:
    		                         
      payment-in-kind interest accrued in prior year added to principal of term loan
    		                         
      deferred merger transaction costs included in accounts payable and accrued professional services
    		                   315,000      
      leasehold improvements paid by landlord
    		               0          
      transfers from
    		                    1,080,000 -3,109,000 11,601,000   
      recognition of property and equipment previously classified in other assets
    		                   0 0 0 10,000,000   
      noncash contribution by a noncontrolling interest
    		               0          
      recognized intangible asset recorded in other accrued and other long-term liabilities
    		                         
      unpaid debt issuance costs
    		                         
      net noncash portion of repurchase of eidos noncontrolling interests
    		               1,000 0 0 38,167,000       
      direct transaction costs in the repurchase of eidos recorded in additional paid-in capital previously classified in prepaid expenses and other current assets
    		               0 0 0 8,749,000       
      reconciliation of cash, cash equivalents and restricted cash
    		                         
      restricted cash
    		                         
      restricted cash - included in other assets
    		                         
      total cash, cash equivalents and restricted cash at end of year
    		                         
      net income from investment in equity securities
    		            -10,259,000 10,362,000 12,866,000           
      proceeds from term loan
    		                0         
      net gains from investment in equity securities
    		                         
      share in net income of equity method investments
    		                         
      acquisition of intangible assets
    		               0          
      others
    		                         
      proceeds from issuance of common stock in connection with initial public offering
    		                         
      proceeds from issuance of noncontrolling interest to alexion
    		                       0  
      proceeds from term loans, net of issuance costs
    		                       17,152,000 0 
      transfers
    		                         
      intangible assets recorded in other accrued and other long-term liabilities
    		                         
      build-to-suit funding liability accrual
    		                         
      fair value of success fee derivative at issuance of eidos term loan
    		                         
      proceeds from disposal of property and equipment
    		                   0 0     
      recognized intangible asset recorded in other accrued liabilities and other long-term liabilities
    		                         
      repurchase of common stock recorded in accounts payable
    		                         
      total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows
    		                         
      other accrued and other liabilities
    		                 6,139,000 -3,540,000 3,445,000 -449,000 5,324,000 15,000   
      investment in equity securities
    		                         
      noncash contribution by an nci
    		                         
      recognized intangible asset recorded in accrued research and development liabilities
    		                         
      leasehold improvement paid by landlord
    		                         
      transfers from noncontrolling interests
    		                 -1,416,000 1,690,000       
      1.
    		                         
      amortization of operating lease right-of-use assets
    		                  1,365,000       
      proceeds from issuance of redeemable convertible noncontrolling interests to third-party investors
    		                   0 1,000,000 0 1,000,000   
      direct transaction costs in the repurchase of eidos noncontrolling interest included in accounts payable and accrued professional services
    		                  4,766,000       
      issuance costs associated with issuance of 2027 notes included in other accrued and other liabilities
    		                      664,000   
      gain on deconsolidation of pellepharm
    		                         
      change in fair value of lianbio warrants
    		                         
      fair value of equity method investment
    		                         
      accretion of 2027 notes and term loans
    		                   5,422,000 5,335,000 5,219,000 1,761,000   
      change in fair value of eidos financial instruments
    		                         
      payments of merger transaction costs
    		                         
      cash paid for in-process research and development assets acquired
    		                       0 0 
      cash and cash equivalents acquired in ml bio asset acquisition
    		                       0  
      proceeds from issuance of common stock in connection with the initial public offering of bridgebio in 2019 and eidos in 2018, net of underwriting discounts and commissions
    		                         
      proceeds from issuance of 2027 notes
    		                   0 0 0 550,000,000   
      issuance costs and discounts associated with issuance of 2027 notes
    		                   0 0 -664,000 -12,375,000   
      proceeds from issuance of promissory notes
    		                         
      proceeds from repayment of nonrecourse notes
    		                       0 0 
      proceeds from the issuance of redeemable convertible preferred units, net of issuance costs
    		                         
      proceeds from repayment of the loans received by noncontrolling interest shareholder
    		                         
      myokardia distributions
    		                       0 0 
      tenant improvement paid by landlord
    		                       1,138,000  
      non-cash contribution by a noncontrolling interest
    		                         
      conversion of redeemable noncontrolling interest into noncontrolling interest
    		                         
      conversion of promissory note into redeemable convertible noncontrolling interest
    		                         
      fair value of redeemable convertible noncontrolling interest issued for acquired in-process research and development assets
    		                         
      proceeds from issuance of common stock in connection with the initial public offering
    		                         
      operating lease right-of-use assets obtained in exchange for operating lease obligations
    		                    0 2,419,000 9,395,000   
      payment of deferred offering costs
    		                         
      deferred offering costs included in accounts payable and other accrued liabilities
    		                         
      accretion of term loans and convertible promissory notes
    		                       787,000 20,000 
      other accrued liabilities
    		                       -1,162,000 2,184,000 
      proceeds from issuance of common stock in connection with the initial public offering of the corporation in 2019 and eidos in 2018, net of underwriting discounts and commissions
    		                         
      proceeds from third-party investors in redeemable convertible noncontrolling interests
    		                       0  
      proceeds from stock option exercises
    		                         
      conversion of promissory note upon issuance of series c redeemable convertible preferred units
    		                         
      capital transaction upon merger
    		                         
      net accretion and amortization of premium and discounts on marketable securities
    		                         
      equity-based compensation
    		                        5,846,000 
      loss on disposal of property and equipment
    		                        55,000 
      income from ml bio asset acquisition
    		                         
      income from pellepharm
    		                        6,589,000 
      shares issued under license agreements
    		                        0 
      proceeds from issuance of bridgebio pharma llc common stock equivalents, net of issuance costs
    		                         
      proceeds from issuance of common stock in connection with the initial public offering, net of underwriting discounts and commissions
    		                         
      proceeds from issuance of common stock in connection with the initial public offering of eidos, net of underwriting discounts and commissions
    		                         
      issuance of loan to noncontrolling interest shareholder
    		                         
      proceeds from subsidiary stock option exercises
    		                        346,000 
      transfers to
    		                        13,529,000 
      proceeds from the issuance of series c preferred units, net of issuance costs
    		                         
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.